Phase 3
Completed N=16
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
Gram-Negative Bacterial Infections · Sepsis
Source: ClinicalTrials.gov NCT00490477 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Jun 2010
Primary outcomePrimary: Number of Participants Not Requiring Renal Replacement Therapy (RRT) — 3; 1 participants
Summary
Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal dysfunction in patients with severe sepsis from gram negative infection.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Not Requiring Renal Replacement Therapy (RRT) |
3; 1 | — |
| SECONDARY The Reduction of the Number of Apoptotic Cells, Stimulated With Plasma Derives From Septic Patients With Gram Negative Infection, Treated With PMX-B Hemoperfusion, on Immortalized Tubular and Glomerular Cell Cultures. |
— | — |
Eligibility Criteria
Inclusion Criteria
- Endotoxemia associated to severe sepsis
Exclusion Criteria
- Age 30
- Lack of consent
Data sourced from ClinicalTrials.gov (NCT00490477). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.